New Experimental Drug Helps Treat Antibiotic Resistant Bacteria

An experimental drug being tested to treat neurodegenerative disease may help fight against life-threatening antibiotic resistant bacteria, suggests a study from Australia.

Bacterial resistance to antibiotics is growing as a worldwide problem. Handling this crisis is getting difficult day by day. Enterobacterales (gram negative bacteria like, E.coli, Klebsiella pneumoniae, Pseudomonas aeruginosa) with resistance to polymyxin class of antibiotics are a major threat.

Beetroot Peptide can Help Treat Alzheimer�s, Hypertension and Diabetes
Peptide isolated from beetroot has shown promise in the treatment of hypertension, diabetes, multiple sclerosis & Alzheimer’s disease due to its anti-inflammatory properties.

‘PBT2, the experimental neurodegenerative drug when combined with polymyxin could disrupt and kill gram negative bacteria that can cause pneumonia, blood stream infections and meningitis. PBT2 is administered orally with a dose of 250 mg once daily. ’
Read More..

Dr. Mark Walker of the University of Queensland in Brisbane and colleagues write in Science Translational Medicine,” The emergence of polymyxin resistance in carbapenem (antibiotic class) -resistant and extended-spectrum beta-lactamase (ESBL)-producing bacteria is a critical threat to human health, and alternative treatment strategies are urgently required. ”

PBT2, the experimental neurodegenerative drug when combined with polymyxin (a class of antibiotics) could disrupt and kill gram negative bacteria that can cause pneumonia, blood stream infections and meningitis (infection in the brain).

PBT2 has undergone the phase 2 clinical trials for neurodegenerative diseases to break polymyxin antibiotic resistance in four gram negative organisms including Klebsiella pneumoniae, Pseudomonas aeruginosa.

PBT2 can be taken orally and shows good absorption in the body. PBT2 is in phase 2 testing in patients with Huntington’s and Alzheimer’s disease.

Huntington’s disease is a progressive brain disorder characterized by uncontrolled movements, emotional problems, loss of thinking ability.

It is given orally,250 mg once daily . This dose is well tolerated and safe for patients when given for periods up to 24 months.

Want to be at a Lower Risk of Diabetes � Which is Better an Eggless or Egg Rich Diet?
Excessive consumption of egg can increase the risk of diabetes states a new research done at the University of South Australia

In a previous study Dr Walker and colleagues found that antibiotic resistance in Gram positive bacteria could be overcome by repurposing PBT2 in combination with zinc. The latest study suggests that PBT2 has the ability to restore antibiotic sensitivity in polymyxin resistant, ESBL producing, carbapenem resistant gram negative human pathogens (bacteria resistant to even the higher classes of antibiotics).

In vitro PBT2 studies were done to resensitize Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa (these are the microorganisms resistant to most of the antibiotic classes) to "last-resort" polymyxin-class antibiotics including the next generation polymyxin derivative FADDI-287 (highest class of antibiotics available).

COVID 19 & Hypercoagulability: Increased Risk of Stroke, Heart Attack, DVT
COVID 19 patients with a history of heart attack, stroke and deep vein thrombosis should receive anticoagulation therapy.

Even highly antibiotic resistant bacteria like K.pneumoniae showed succeptibility to the combination of PBT2 and polymyxin. This combination has successfully treated gram negative sepsis.

"The mechanism of action responsible for this effect appears to be mediated throughdysregulation of bacterial metal ion homeostasis," the researchers write.

Prolonged Androgen Deprivation Therapy Increases Risk of CV Death in Prostate Cancer Patients
Prolonged ADT therapy regimen and increased intensity of therapy is associated with increased cardiovascular mortality.

Dr. Walker told,” Demonstration of in vivo efficacy against Klebsiella sepsis in a mouse model (and) provides a new strategy for rescuing antibiotics that have lost efficacy due to antibiotic resistance development. We are looking towards undertaking a human trial of antibiotic in combination with PBT2 “

Source-Medindia